Systemic Minoxidil for Hair Disorders in Pediatric Patients: A Safety and Tolerability Review

In this study, low-dose oral minoxidil and sublingual minoxidil were generally well-tolerated in children with alopecia, with mild hypertrichosis as the most common adverse event.

This study reviewed literature on low-dose oral minoxidil as a treatment for hair loss, finding good compliance and tolerability, with mild adverse effects like hypertrichosis, which increase with higher doses.

In this study, low-dose oral minoxidil for hair loss was associated with infrequent systemic adverse effects, and only 1.7% of patients discontinued treatment due to these effects.

This case report describes a 27-year-old woman who experienced facial swelling due to allergic contact dermatitis from using minoxidil 5% foam.

This study found that low-dose oral minoxidil for androgenetic alopecia was associated with a higher incidence of hypertrichosis and edema compared to previous studies, but it remains a generally well-tolerated treatment option.

This study found that low-dose oral minoxidil 5 mg daily significantly increased hair growth in men with androgenetic alopecia over 24 weeks, with increased hair count and vertex area improvement, though most experienced hypertrichosis and some had pedal edema.

This review article provides an updated overview of the pharmacology, mechanism of action, clinical efficacy, and adverse events associated with topical minoxidil, a widely used treatment for androgenetic alopecia and other hair loss conditions, while noting that its exact mechanism is still not fully understood.

This study found that platelet-rich plasma injections improved hair density and diameter in women with androgenetic alopecia not responding to other treatments over 24 weeks, with no adverse events reported.

Minoxidil promotes hair regrowth, but more research needed for effectiveness and response factors.